These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11098350)

  • 1. Spironolactone in the treatment of congestive heart failure.
    Lloyd SJ; Mauro VF
    Ann Pharmacother; 2000 Nov; 34(11):1336-40. PubMed ID: 11098350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
    Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of the RALE study. Hyperkalemia following spironolactone treatment].
    Erdmann E
    Internist (Berl); 2005 Apr; 46(4):466, 468. PubMed ID: 15723149
    [No Abstract]   [Full Text] [Related]  

  • 12. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race influences the safety and efficacy of spironolactone in severe heart failure.
    Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
    Talatinian A; Chow SL; Heywood JT
    Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
    Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
    Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.
    Bozkurt B; Agoston I; Knowlton AA
    J Am Coll Cardiol; 2003 Jan; 41(2):211-4. PubMed ID: 12535810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
    Haller C
    Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.